Evidence map›Paper›PMID 40765809›Full record

ArticleNagoya journal of medical science2025

Durvalumab-combined chemotherapy for biliary tract cancer in a Japanese expert center: initial 50 cases in daily practice.

Yoshikuni Inokawa, Shunsuke Onoe, Shoji Kawakatsu, Masamichi Hayashi, Nobuyuki Watanabe, Osamu Maeda, Takashi Mizuno, Hideki Takami, Hiroki Kawashima, Yuichi Ando and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nagoya journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoshikuni InokawaDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shunsuke OnoeDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shoji KawakatsuDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masamichi HayashiDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nobuyuki WatanabeDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Osamu MaedaDepartment of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Takashi MizunoDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hideki TakamiDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hiroki KawashimaDepartment of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yuichi AndoDepartment of Clinical Oncology and Chemotherapy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tomoki EbataDepartment of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination regimen consisting of gemcitabine, cisplatin, and durvalumab (GCD) has been employed for unresectable biliary tract cancer (BTC) since the end of 2022 in Japan. Here, we summarize our experience with GCD to demonstrate the clinical outcomes in a practical setting. Patients who underwent GCD for unresectable/recurrent BTC between January and December 2023 were investigated retrospectively. Data for maximal response rate (RR), disease control rate (DCR), and adverse events (AEs) were collected. Progression-free survival (PFS) and overall survival (OS) curves were generated using the Kaplan-Meyer method. Fifty (initially unresectable, n = 32; recurrence after surgery, n = 18) consecutive patients were enrolled, 19 of whom started GCD as second-line therapy or later. Overall RR was 24.0% including complete response in 1 (2%) patient and partial response in 11 (22%) patients; DCR was 68.0%. The median PFS and OS were 7.1 months and not reached, respectively. During a median follow-up period of 8.5 months, 8 (16%) patients underwent surgical resection. A total of 36 (72%) patients suffered Grade 3-5 AE, and 3 immune-related AE were controlled with injection of corticosteroid or observation. The efficacy of GCD for unresectable/recurrent BTC was confirmed in the practical setting, with acceptable toxicity, prolonged survival, and potential probability of resection.

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsAdultAgedAged, 80 and overCisplatinDeoxycytidineEast Asian PeopleFemaleGemcitabineHumansJapanMaleMiddle AgedRetrospective StudiesAntibodies, MonoclonalCisplatinDeoxycytidinedurvalumabGemcitabinebiliary tract cancerdurvalumabimmune related adverse eventprognosisunresectable

Identifiers

PMID40765809
PMCPMC12320298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.